Retrospective review for outcomes of IDH mutant, 1p/19q co-deleted gliomas based on initial treatment. This is an ASCO Meeting Abstract from the 2019 ASCO Annual Meeting I. This abstract does not ...

Adding a targeted agent to chemotherapy failed to improve survival as initial therapy for metastatic urothelial carcinoma, a randomized trial showed. Median overall survival (OS) was about 14 months ...

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency ...

Bevacizumab biosimilar LY01008 demonstrated comparative safety, efficacy, immunogenicity, and pharmacokinetic profiles to the reference product Avastin when combined with paclitaxel and carboplatin in ...

Please provide your email address to receive an email when new articles are posted on . When added to chemotherapy, extending the duration of bevacizumab treatment from 15 to 30 months failed to ...

The combination of atezolizumab plus bevacizumab could become a standard first-line treatment for patients with metastatic nonsquamous non–small cell lung cancer (NSCLC) with high tumor mutation ...

Compared with chemotherapy alone, 1L chemotherapy plus bevacizumab was associated with a trend toward longer median real-world overall survival. HealthDay News — The addition of bevacizumab to ...

Corey J. Langer, MD, FACP: Personally, I believe there’s still a role for bevacizumab in select patients despite the astounding survival advantages seen with KEYNOTE-189. There are patients who aren’t ...

Bevacizumab (Avastin, Roche/Genentech) significantly extended survival by nearly 4 months in patients with advanced, recurrent, or persistent cervical cancer that was not curable with standard surgery ...

Please provide your email address to receive an email when new articles are posted on . Patients treated with a step therapy protocol of bevacizumab injections for neovascular age-related macular ...